A phase I study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of ocular GLH8NDE in healthy male adults.

Furthermore, GLH8NDE at 9 and 36 mg/day showed an increasing tendency in TBUT from baseline (Figure 2 ) although the changes were within the normal range and failed to reach statistical significance.

also in 6,035 other papers

Pharmacodynamic evaluation GLH8NDE, particularly at 9 and 36 mg/day, increased TBUT from baseline in both eyes, although it did not reach statistical significance (Figure 2 ).

also in 111,027 other papers